id	sid	tid	token	lemma	pos
dpc-2041	1	1	dermatology	dermatology	NOUN
dpc-2041	1	2	:	:	PUNCT
dpc-2041	1	3	practical	practical	ADJ
dpc-2041	1	4	and	and	CCONJ
dpc-2041	1	5	conceptual	conceptual	ADJ
dpc-2041	1	6	research	research	NOUN
dpc-2041	1	7	letter	letter	NOUN
dpc-2041	2	1	|	|	ADV
dpc-2041	2	2	dermatol	dermatol	ADJ
dpc-2041	2	3	pract	pract	NOUN
dpc-2041	2	4	concept	concept	NOUN
dpc-2041	2	5	.	.	PUNCT
dpc-2041	3	1	2022;12(3):e2022132	2022;12(3):e2022132	NUM
dpc-2041	3	2	1	1	NUM
dpc-2041	3	3	lymphoma	lymphoma	NOUN
dpc-2041	3	4	developing	develop	VERB
dpc-2041	3	5	in	in	ADP
dpc-2041	3	6	a	a	DET
dpc-2041	3	7	patient	patient	NOUN
dpc-2041	3	8	with	with	ADP
dpc-2041	3	9	long	long	ADJ
dpc-2041	3	10	-	-	PUNCT
dpc-2041	3	11	term	term	NOUN
dpc-2041	3	12	antitumor	antitumor	PROPN
dpc-2041	3	13	necrosis	necrosis	NOUN
dpc-2041	3	14	factor	factor	NOUN
dpc-2041	3	15	therapy	therapy	NOUN
dpc-2041	3	16	giovana	giovana	PROPN
dpc-2041	3	17	serrão	serrão	PROPN
dpc-2041	3	18	fensterseifer1	fensterseifer1	PROPN
dpc-2041	3	19	,	,	PUNCT
dpc-2041	3	20	andré	andré	VERB
dpc-2041	3	21	carvalho2	carvalho2	PROPN
dpc-2041	3	22	,	,	PUNCT
dpc-2041	3	23	ana	ana	PROPN
dpc-2041	3	24	letícia	letícia	PROPN
dpc-2041	3	25	boff3	boff3	PROPN
dpc-2041	3	26	,	,	PUNCT
dpc-2041	3	27	joel	joel	PROPN
dpc-2041	3	28	schwartz4	schwartz4	PROPN
dpc-2041	3	29	1	1	NUM
dpc-2041	3	30	dermatologist	dermatologist	NOUN
dpc-2041	3	31	at	at	ADP
dpc-2041	3	32	private	private	ADJ
dpc-2041	3	33	practice	practice	NOUN
dpc-2041	3	34	,	,	PUNCT
dpc-2041	3	35	dermatologist	dermatologist	NOUN
dpc-2041	3	36	at	at	ADP
dpc-2041	3	37	dermatology	dermatology	NOUN
dpc-2041	3	38	department	department	PROPN
dpc-2041	3	39	at	at	ADP
dpc-2041	3	40	hospital	hospital	PROPN
dpc-2041	3	41	são	são	PROPN
dpc-2041	3	42	lucas	lucas	PROPN
dpc-2041	3	43	da	da	PROPN
dpc-2041	3	44	pucrs	pucrs	PROPN
dpc-2041	3	45	,	,	PUNCT
dpc-2041	3	46	porto	porto	PROPN
dpc-2041	3	47	alegrebrazil	alegrebrazil	PROPN
dpc-2041	3	48	2	2	NUM
dpc-2041	3	49	dermatologist	dermatologist	NOUN
dpc-2041	3	50	at	at	ADP
dpc-2041	3	51	private	private	ADJ
dpc-2041	3	52	practice	practice	NOUN
dpc-2041	3	53	,	,	PUNCT
dpc-2041	3	54	dermatologist	dermatologist	NOUN
dpc-2041	3	55	at	at	ADP
dpc-2041	3	56	hospital	hospital	NOUN
dpc-2041	3	57	moinhos	moinhos	PROPN
dpc-2041	3	58	de	de	PROPN
dpc-2041	3	59	vento	vento	PROPN
dpc-2041	3	60	,	,	PUNCT
dpc-2041	3	61	porto	porto	PROPN
dpc-2041	3	62	alegrebrazil	alegrebrazil	PROPN
dpc-2041	3	63	3	3	NUM
dpc-2041	3	64	pathologist	pathologist	NOUN
dpc-2041	3	65	at	at	ADP
dpc-2041	3	66	private	private	ADJ
dpc-2041	3	67	practice	practice	NOUN
dpc-2041	3	68	,	,	PUNCT
dpc-2041	3	69	pathologist	pathologist	NOUN
dpc-2041	3	70	at	at	ADP
dpc-2041	3	71	dermatology	dermatology	NOUN
dpc-2041	3	72	department	department	PROPN
dpc-2041	3	73	at	at	ADP
dpc-2041	3	74	santa	santa	PROPN
dpc-2041	3	75	casa	casa	PROPN
dpc-2041	3	76	de	de	PROPN
dpc-2041	3	77	misericórdia	misericórdia	PROPN
dpc-2041	3	78	de	de	PROPN
dpc-2041	3	79	porto	porto	PROPN
dpc-2041	3	80	alegre	alegre	PROPN
dpc-2041	3	81	,	,	PUNCT
dpc-2041	3	82	porto	porto	PROPN
dpc-2041	3	83	alegrebrazil	alegrebrazil	PROPN
dpc-2041	3	84	4	4	NUM
dpc-2041	3	85	dermatologist	dermatologist	NOUN
dpc-2041	3	86	at	at	ADP
dpc-2041	3	87	private	private	ADJ
dpc-2041	3	88	practice	practice	NOUN
dpc-2041	3	89	,	,	PUNCT
dpc-2041	3	90	porto	porto	PROPN
dpc-2041	3	91	alegrebrazil	alegrebrazil	PROPN
dpc-2041	3	92	key	key	ADJ
dpc-2041	3	93	words	word	NOUN
dpc-2041	3	94	:	:	PUNCT
dpc-2041	3	95	lymphoma	lymphoma	NOUN
dpc-2041	3	96	,	,	PUNCT
dpc-2041	3	97	antitnf	antitnf	ADJ
dpc-2041	3	98	,	,	PUNCT
dpc-2041	3	99	adalimumab	adalimumab	NOUN
dpc-2041	3	100	,	,	PUNCT
dpc-2041	3	101	psoriasis	psoriasis	NOUN
dpc-2041	3	102	citation	citation	NOUN
dpc-2041	3	103	:	:	PUNCT
dpc-2041	3	104	fensterseifer	fensterseifer	PROPN
dpc-2041	3	105	gs	gs	PROPN
dpc-2041	3	106	,	,	PUNCT
dpc-2041	3	107	carvalho	carvalho	NOUN
dpc-2041	3	108	a	a	PRON
dpc-2041	3	109	,	,	PUNCT
dpc-2041	3	110	boff	boff	PROPN
dpc-2041	3	111	al	al	PROPN
dpc-2041	3	112	,	,	PUNCT
dpc-2041	3	113	schwartz	schwartz	PROPN
dpc-2041	3	114	j.	j.	PROPN
dpc-2041	3	115	lymphoma	lymphoma	PROPN
dpc-2041	3	116	developing	develop	VERB
dpc-2041	3	117	in	in	ADP
dpc-2041	3	118	a	a	DET
dpc-2041	3	119	patient	patient	NOUN
dpc-2041	3	120	with	with	ADP
dpc-2041	3	121	long	long	ADJ
dpc-2041	3	122	-	-	PUNCT
dpc-2041	3	123	term	term	NOUN
dpc-2041	3	124	antitumor	antitumor	PROPN
dpc-2041	3	125	necrosis	necrosis	NOUN
dpc-2041	3	126	factor	factor	NOUN
dpc-2041	3	127	therapy	therapy	NOUN
dpc-2041	3	128	.	.	PUNCT
dpc-2041	4	1	dermatol	dermatol	NOUN
dpc-2041	4	2	pract	pract	PROPN
dpc-2041	4	3	concept	concept	NOUN
dpc-2041	4	4	.	.	PUNCT
dpc-2041	5	1	2022;12(3):e2022132	2022;12(3):e2022132	X
dpc-2041	5	2	.	.	PUNCT
dpc-2041	6	1	doi	doi	PROPN
dpc-2041	6	2	:	:	PUNCT
dpc-2041	6	3	https://doi.org/10.5826/dpc.1203a132	https://doi.org/10.5826/dpc.1203a132	NOUN
dpc-2041	6	4	accepted	accept	VERB
dpc-2041	6	5	:	:	PUNCT
dpc-2041	6	6	december	december	PROPN
dpc-2041	6	7	6	6	NUM
dpc-2041	6	8	,	,	PUNCT
dpc-2041	6	9	2021	2021	NUM
dpc-2041	6	10	;	;	PUNCT
dpc-2041	6	11	published	publish	VERB
dpc-2041	6	12	:	:	PUNCT
dpc-2041	7	1	july	july	PROPN
dpc-2041	7	2	2022	2022	NUM
dpc-2041	7	3	copyright	copyright	NOUN
dpc-2041	7	4	:	:	PUNCT
dpc-2041	7	5	©	©	PROPN
dpc-2041	7	6	2022	2022	NUM
dpc-2041	7	7	fensterseifer	fensterseifer	NOUN
dpc-2041	7	8	et	et	PROPN
dpc-2041	7	9	al	al	PROPN
dpc-2041	7	10	.	.	PUNCT
dpc-2041	8	1	this	this	PRON
dpc-2041	8	2	is	be	AUX
dpc-2041	8	3	an	an	DET
dpc-2041	8	4	open	open	ADJ
dpc-2041	8	5	-	-	PUNCT
dpc-2041	8	6	access	access	NOUN
dpc-2041	8	7	article	article	NOUN
dpc-2041	8	8	distributed	distribute	VERB
dpc-2041	8	9	under	under	ADP
dpc-2041	8	10	the	the	DET
dpc-2041	8	11	terms	term	NOUN
dpc-2041	8	12	of	of	ADP
dpc-2041	8	13	the	the	DET
dpc-2041	8	14	creative	creative	ADJ
dpc-2041	8	15	commons	common	NOUN
dpc-2041	8	16	attribution	attribution	NOUN
dpc-2041	8	17	license	license	NOUN
dpc-2041	8	18	(	(	PUNCT
dpc-2041	8	19	by	by	ADP
dpc-2041	8	20	-	-	PUNCT
dpc-2041	8	21	nc-4.0	nc-4.0	NOUN
dpc-2041	8	22	)	)	PUNCT
dpc-2041	8	23	,	,	PUNCT
dpc-2041	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2041	8	25	which	which	PRON
dpc-2041	8	26	permits	permit	VERB
dpc-2041	8	27	unrestricted	unrestricted	ADJ
dpc-2041	8	28	noncommercial	noncommercial	ADJ
dpc-2041	8	29	use	use	NOUN
dpc-2041	8	30	,	,	PUNCT
dpc-2041	8	31	distribution	distribution	NOUN
dpc-2041	8	32	,	,	PUNCT
dpc-2041	8	33	and	and	CCONJ
dpc-2041	8	34	reproduction	reproduction	NOUN
dpc-2041	8	35	in	in	ADP
dpc-2041	8	36	any	any	DET
dpc-2041	8	37	medium	medium	NOUN
dpc-2041	8	38	,	,	PUNCT
dpc-2041	8	39	provided	provide	VERB
dpc-2041	8	40	the	the	DET
dpc-2041	8	41	original	original	ADJ
dpc-2041	8	42	authors	author	NOUN
dpc-2041	8	43	and	and	CCONJ
dpc-2041	8	44	source	source	NOUN
dpc-2041	8	45	are	be	AUX
dpc-2041	8	46	credited	credit	VERB
dpc-2041	8	47	.	.	PUNCT
dpc-2041	9	1	funding	funding	NOUN
dpc-2041	9	2	:	:	PUNCT
dpc-2041	9	3	none	none	NOUN
dpc-2041	9	4	.	.	PUNCT
dpc-2041	10	1	competing	compete	VERB
dpc-2041	10	2	interests	interest	NOUN
dpc-2041	10	3	:	:	PUNCT
dpc-2041	10	4	none	none	NOUN
dpc-2041	10	5	.	.	PUNCT
dpc-2041	11	1	authorship	authorship	NOUN
dpc-2041	11	2	:	:	PUNCT
dpc-2041	11	3	all	all	DET
dpc-2041	11	4	authors	author	NOUN
dpc-2041	11	5	have	have	AUX
dpc-2041	11	6	contributed	contribute	VERB
dpc-2041	11	7	significantly	significantly	ADV
dpc-2041	11	8	to	to	ADP
dpc-2041	11	9	this	this	DET
dpc-2041	11	10	publication	publication	NOUN
dpc-2041	11	11	.	.	PUNCT
dpc-2041	12	1	corresponding	correspond	VERB
dpc-2041	12	2	author	author	NOUN
dpc-2041	12	3	:	:	PUNCT
dpc-2041	12	4	giovana	giovana	PROPN
dpc-2041	12	5	serrão	serrão	PROPN
dpc-2041	12	6	fensterseifer	fensterseifer	PROPN
dpc-2041	12	7	,	,	PUNCT
dpc-2041	12	8	md	md	PROPN
dpc-2041	12	9	,	,	PUNCT
dpc-2041	12	10	rua	rua	PROPN
dpc-2041	12	11	professor	professor	PROPN
dpc-2041	12	12	langendonck	langendonck	ADJ
dpc-2041	12	13	,	,	PUNCT
dpc-2041	12	14	117	117	NUM
dpc-2041	12	15	.	.	PUNCT
dpc-2041	13	1	porto	porto	PROPN
dpc-2041	13	2	alegrebrazil	alegrebrazil	PROPN
dpc-2041	13	3	,	,	PUNCT
dpc-2041	13	4	+55	+55	PROPN
dpc-2041	13	5	51	51	NUM
dpc-2041	13	6	99240	99240	NUM
dpc-2041	13	7	-	-	SYM
dpc-2041	13	8	4660	4660	NUM
dpc-2041	13	9	,	,	PUNCT
dpc-2041	13	10	e	e	NOUN
dpc-2041	13	11	-	-	NOUN
dpc-2041	13	12	mail	mail	NOUN
dpc-2041	13	13	:	:	PUNCT
dpc-2041	13	14	gfensterseifer@gmail.com	gfensterseifer@gmail.com	X
dpc-2041	13	15	dermatology	dermatology	NOUN
dpc-2041	13	16	practical	practical	ADJ
dpc-2041	13	17	&	&	CCONJ
dpc-2041	13	18	conceptual	conceptual	ADJ
dpc-2041	13	19	introduction	introduction	NOUN
dpc-2041	13	20	some	some	DET
dpc-2041	13	21	studies	study	NOUN
dpc-2041	13	22	have	have	AUX
dpc-2041	13	23	shown	show	VERB
dpc-2041	13	24	that	that	SCONJ
dpc-2041	13	25	tumor	tumor	NOUN
dpc-2041	13	26	necrosis	necrosis	NOUN
dpc-2041	13	27	factor	factor	NOUN
dpc-2041	13	28	(	(	PUNCT
dpc-2041	13	29	tnf	tnf	PROPN
dpc-2041	13	30	)	)	PUNCT
dpc-2041	13	31	alfa	alfa	NOUN
dpc-2041	13	32	inhibitor	inhibitor	NOUN
dpc-2041	13	33	therapy	therapy	NOUN
dpc-2041	13	34	may	may	AUX
dpc-2041	13	35	increase	increase	VERB
dpc-2041	13	36	the	the	DET
dpc-2041	13	37	risk	risk	NOUN
dpc-2041	13	38	of	of	ADP
dpc-2041	13	39	lymphomas	lymphoma	NOUN
dpc-2041	13	40	[	[	X
dpc-2041	13	41	1	1	NUM
dpc-2041	13	42	]	]	PUNCT
dpc-2041	13	43	.	.	PUNCT
dpc-2041	14	1	it	it	PRON
dpc-2041	14	2	is	be	AUX
dpc-2041	14	3	historically	historically	ADV
dpc-2041	14	4	known	know	VERB
dpc-2041	14	5	that	that	SCONJ
dpc-2041	14	6	psoriasis	psoriasis	NOUN
dpc-2041	14	7	can	can	AUX
dpc-2041	14	8	also	also	ADV
dpc-2041	14	9	increase	increase	VERB
dpc-2041	14	10	the	the	DET
dpc-2041	14	11	risk	risk	NOUN
dpc-2041	14	12	of	of	ADP
dpc-2041	14	13	cutaneous	cutaneous	ADJ
dpc-2041	14	14	lymphomas	lymphoma	NOUN
dpc-2041	14	15	.	.	PUNCT
dpc-2041	15	1	here	here	ADV
dpc-2041	15	2	we	we	PRON
dpc-2041	15	3	present	present	VERB
dpc-2041	15	4	a	a	DET
dpc-2041	15	5	case	case	NOUN
dpc-2041	15	6	of	of	ADP
dpc-2041	15	7	a	a	DET
dpc-2041	15	8	primary	primary	ADJ
dpc-2041	15	9	cutaneous	cutaneous	ADJ
dpc-2041	15	10	anaplastic	anaplastic	ADJ
dpc-2041	15	11	large	large	ADJ
dpc-2041	15	12	cell	cell	NOUN
dpc-2041	15	13	lymphoma	lymphoma	NOUN
dpc-2041	15	14	in	in	ADP
dpc-2041	15	15	a	a	DET
dpc-2041	15	16	patient	patient	NOUN
dpc-2041	15	17	under	under	ADP
dpc-2041	15	18	treatment	treatment	NOUN
dpc-2041	15	19	with	with	ADP
dpc-2041	15	20	adalimumab	adalimumab	NOUN
dpc-2041	15	21	for	for	ADP
dpc-2041	15	22	psoriasis	psoriasis	NOUN
dpc-2041	15	23	and	and	CCONJ
dpc-2041	15	24	psoriatic	psoriatic	ADJ
dpc-2041	15	25	arthritis	arthritis	NOUN
dpc-2041	15	26	.	.	PUNCT
dpc-2041	16	1	case	case	NOUN
dpc-2041	16	2	presentation	presentation	NOUN
dpc-2041	16	3	patient	patient	NOUN
dpc-2041	16	4	presented	present	VERB
dpc-2041	16	5	to	to	ADP
dpc-2041	16	6	the	the	DET
dpc-2041	16	7	clinic	clinic	NOUN
dpc-2041	16	8	with	with	ADP
dpc-2041	16	9	a	a	DET
dpc-2041	16	10	shallow	shallow	ADJ
dpc-2041	16	11	one	one	NUM
dpc-2041	16	12	-	-	PUNCT
dpc-2041	16	13	month	month	NOUN
dpc-2041	16	14	ulcerative	ulcerative	ADJ
dpc-2041	16	15	lesion	lesion	NOUN
dpc-2041	16	16	,	,	PUNCT
dpc-2041	16	17	with	with	ADP
dpc-2041	16	18	infiltrated	infiltrate	VERB
dpc-2041	16	19	borders	border	NOUN
dpc-2041	16	20	on	on	ADP
dpc-2041	16	21	the	the	DET
dpc-2041	16	22	buttock	buttock	NOUN
dpc-2041	16	23	.	.	PUNCT
dpc-2041	17	1	the	the	DET
dpc-2041	17	2	patient	patient	NOUN
dpc-2041	17	3	had	have	AUX
dpc-2041	17	4	been	be	AUX
dpc-2041	17	5	on	on	ADP
dpc-2041	17	6	adalimumab	adalimumab	NOUN
dpc-2041	17	7	for	for	ADP
dpc-2041	17	8	,	,	PUNCT
dpc-2041	17	9	approximately	approximately	ADV
dpc-2041	17	10	,	,	PUNCT
dpc-2041	17	11	the	the	DET
dpc-2041	17	12	last	last	ADJ
dpc-2041	17	13	10	10	NUM
dpc-2041	17	14	years	year	NOUN
dpc-2041	17	15	due	due	ADP
dpc-2041	17	16	to	to	ADP
dpc-2041	17	17	psoriasis	psoriasis	NOUN
dpc-2041	17	18	and	and	CCONJ
dpc-2041	17	19	psoriatic	psoriatic	ADJ
dpc-2041	17	20	arthritis	arthritis	NOUN
dpc-2041	17	21	(	(	PUNCT
dpc-2041	17	22	figure	figure	NOUN
dpc-2041	17	23	1	1	NUM
dpc-2041	17	24	)	)	PUNCT
dpc-2041	17	25	.	.	PUNCT
dpc-2041	18	1	a	a	DET
dpc-2041	18	2	biopsy	biopsy	NOUN
dpc-2041	18	3	was	be	AUX
dpc-2041	18	4	performed	perform	VERB
dpc-2041	18	5	for	for	ADP
dpc-2041	18	6	histopathology	histopathology	NOUN
dpc-2041	18	7	and	and	CCONJ
dpc-2041	18	8	immunohistochemistry	immunohistochemistry	NOUN
dpc-2041	18	9	analysis	analysis	NOUN
dpc-2041	18	10	.	.	PUNCT
dpc-2041	19	1	the	the	DET
dpc-2041	19	2	report	report	NOUN
dpc-2041	19	3	showed	show	VERB
dpc-2041	19	4	cohesive	cohesive	ADJ
dpc-2041	19	5	sheets	sheet	NOUN
dpc-2041	19	6	of	of	ADP
dpc-2041	19	7	large	large	ADJ
dpc-2041	19	8	cd30	cd30	PROPN
dpc-2041	19	9	-	-	PUNCT
dpc-2041	19	10	positive	positive	ADJ
dpc-2041	19	11	anaplastic	anaplastic	ADJ
dpc-2041	19	12	cells	cell	NOUN
dpc-2041	19	13	confirming	confirm	VERB
dpc-2041	19	14	the	the	DET
dpc-2041	19	15	figure	figure	NOUN
dpc-2041	19	16	1	1	NUM
dpc-2041	19	17	.	.	PUNCT
dpc-2041	19	18	ulcer	ulcer	NOUN
dpc-2041	19	19	on	on	ADP
dpc-2041	19	20	the	the	DET
dpc-2041	19	21	buttock	buttock	NOUN
dpc-2041	19	22	.	.	PUNCT
dpc-2041	20	1	2	2	NUM
dpc-2041	20	2	research	research	NOUN
dpc-2041	20	3	letter	letter	NOUN
dpc-2041	20	4	|	|	ADV
dpc-2041	20	5	dermatol	dermatol	ADJ
dpc-2041	20	6	pract	pract	NOUN
dpc-2041	20	7	concept	concept	NOUN
dpc-2041	20	8	.	.	PUNCT
dpc-2041	21	1	2022;12(3):e2022132	2022;12(3):e2022132	NUM
dpc-2041	21	2	diagnosis	diagnosis	NOUN
dpc-2041	21	3	of	of	ADP
dpc-2041	21	4	cd30	cd30	PROPN
dpc-2041	21	5	+	+	ADP
dpc-2041	21	6	anaplastic	anaplastic	ADJ
dpc-2041	21	7	t	t	NOUN
dpc-2041	21	8	-	-	PUNCT
dpc-2041	21	9	cell	cell	NOUN
dpc-2041	21	10	lymphoma	lymphoma	NOUN
dpc-2041	21	11	.	.	PUNCT
dpc-2041	22	1	staging	stage	VERB
dpc-2041	22	2	determined	determine	VERB
dpc-2041	22	3	a	a	DET
dpc-2041	22	4	cutaneous	cutaneous	ADJ
dpc-2041	22	5	primary	primary	ADJ
dpc-2041	22	6	lymphoma	lymphoma	NOUN
dpc-2041	22	7	with	with	ADP
dpc-2041	22	8	no	no	DET
dpc-2041	22	9	other	other	ADJ
dpc-2041	22	10	organs	organ	NOUN
dpc-2041	22	11	involved	involve	VERB
dpc-2041	22	12	.	.	PUNCT
dpc-2041	23	1	the	the	DET
dpc-2041	23	2	patient	patient	NOUN
dpc-2041	23	3	is	be	AUX
dpc-2041	23	4	currently	currently	ADV
dpc-2041	23	5	under	under	ADP
dpc-2041	23	6	treatment	treatment	NOUN
dpc-2041	23	7	for	for	ADP
dpc-2041	23	8	the	the	DET
dpc-2041	23	9	disease	disease	NOUN
dpc-2041	23	10	(	(	PUNCT
dpc-2041	23	11	figure	figure	NOUN
dpc-2041	23	12	2	2	NUM
dpc-2041	23	13	)	)	PUNCT
dpc-2041	23	14	.	.	PUNCT
dpc-2041	24	1	conclusions	conclusion	NOUN
dpc-2041	24	2	studies	study	NOUN
dpc-2041	24	3	have	have	AUX
dpc-2041	24	4	shown	show	VERB
dpc-2041	24	5	that	that	SCONJ
dpc-2041	24	6	the	the	DET
dpc-2041	24	7	most	most	ADV
dpc-2041	24	8	common	common	ADJ
dpc-2041	24	9	lymphoma	lymphoma	NOUN
dpc-2041	24	10	subtype	subtype	NOUN
dpc-2041	24	11	associated	associate	VERB
dpc-2041	24	12	with	with	ADP
dpc-2041	24	13	anti	anti	ADJ
dpc-2041	24	14	-	-	ADJ
dpc-2041	24	15	tnf	tnf	ADJ
dpc-2041	24	16	therapy	therapy	NOUN
dpc-2041	24	17	is	be	AUX
dpc-2041	24	18	non	non	ADJ
dpc-2041	24	19	-	-	ADJ
dpc-2041	24	20	hodgkin	hodgkin	ADJ
dpc-2041	24	21	b	b	NOUN
dpc-2041	24	22	-	-	PUNCT
dpc-2041	24	23	cell	cell	NOUN
dpc-2041	24	24	lymphoma	lymphoma	NOUN
dpc-2041	25	1	[	[	X
dpc-2041	25	2	1	1	NUM
dpc-2041	25	3	]	]	PUNCT
dpc-2041	25	4	.	.	PUNCT
dpc-2041	26	1	in	in	ADP
dpc-2041	26	2	the	the	DET
dpc-2041	26	3	other	other	ADJ
dpc-2041	26	4	hand	hand	NOUN
dpc-2041	26	5	,	,	PUNCT
dpc-2041	26	6	it	it	PRON
dpc-2041	26	7	is	be	AUX
dpc-2041	26	8	known	know	VERB
dpc-2041	26	9	that	that	SCONJ
dpc-2041	26	10	psoriasis	psoriasis	NOUN
dpc-2041	26	11	itself	itself	PRON
dpc-2041	26	12	can	can	AUX
dpc-2041	26	13	increase	increase	VERB
dpc-2041	26	14	the	the	DET
dpc-2041	26	15	risk	risk	NOUN
dpc-2041	26	16	of	of	ADP
dpc-2041	26	17	cutaneous	cutaneous	ADJ
dpc-2041	26	18	lymphoma	lymphoma	NOUN
dpc-2041	26	19	.	.	PUNCT
dpc-2041	27	1	in	in	ADP
dpc-2041	27	2	this	this	DET
dpc-2041	27	3	case	case	NOUN
dpc-2041	27	4	,	,	PUNCT
dpc-2041	27	5	t	t	NOUN
dpc-2041	27	6	-	-	PUNCT
dpc-2041	27	7	cell	cell	NOUN
dpc-2041	27	8	lymphoma	lymphoma	NOUN
dpc-2041	27	9	is	be	AUX
dpc-2041	27	10	the	the	DET
dpc-2041	27	11	most	most	ADV
dpc-2041	27	12	associated	associated	ADJ
dpc-2041	27	13	lymphoma	lymphoma	NOUN
dpc-2041	27	14	subtype	subtype	NOUN
dpc-2041	27	15	,	,	PUNCT
dpc-2041	27	16	mainly	mainly	ADV
dpc-2041	27	17	mycosis	mycosis	NOUN
dpc-2041	27	18	fungoides	fungoide	NOUN
dpc-2041	27	19	.	.	PUNCT
dpc-2041	28	1	our	our	PRON
dpc-2041	28	2	patient	patient	NOUN
dpc-2041	28	3	presented	present	VERB
dpc-2041	28	4	a	a	DET
dpc-2041	28	5	primary	primary	ADJ
dpc-2041	28	6	cutaneous	cutaneous	ADJ
dpc-2041	28	7	anaplastic	anaplastic	ADJ
dpc-2041	28	8	large	large	ADJ
dpc-2041	28	9	cell	cell	NOUN
dpc-2041	28	10	lymphoma	lymphoma	NOUN
dpc-2041	28	11	.	.	PUNCT
dpc-2041	29	1	this	this	DET
dpc-2041	29	2	subtype	subtype	NOUN
dpc-2041	29	3	of	of	ADP
dpc-2041	29	4	cutaneous	cutaneous	ADJ
dpc-2041	29	5	t	t	PROPN
dpc-2041	29	6	-	-	PUNCT
dpc-2041	29	7	cell	cell	NOUN
dpc-2041	29	8	lymphoma	lymphoma	NOUN
dpc-2041	29	9	usually	usually	ADV
dpc-2041	29	10	presents	present	VERB
dpc-2041	29	11	as	as	ADP
dpc-2041	29	12	a	a	DET
dpc-2041	29	13	solitary	solitary	ADJ
dpc-2041	29	14	nodule	nodule	NOUN
dpc-2041	29	15	that	that	PRON
dpc-2041	29	16	often	often	ADV
dpc-2041	29	17	develops	develop	VERB
dpc-2041	29	18	ulceration	ulceration	NOUN
dpc-2041	29	19	,	,	PUNCT
dpc-2041	29	20	as	as	SCONJ
dpc-2041	29	21	presented	present	VERB
dpc-2041	29	22	in	in	ADP
dpc-2041	29	23	this	this	DET
dpc-2041	29	24	case	case	NOUN
dpc-2041	29	25	.	.	PUNCT
dpc-2041	30	1	the	the	DET
dpc-2041	30	2	prognosis	prognosis	NOUN
dpc-2041	30	3	is	be	AUX
dpc-2041	30	4	usually	usually	ADV
dpc-2041	30	5	favorable	favorable	ADJ
dpc-2041	30	6	with	with	ADP
dpc-2041	30	7	extracutaneous	extracutaneous	ADJ
dpc-2041	30	8	dissemination	dissemination	NOUN
dpc-2041	30	9	occurring	occur	VERB
dpc-2041	30	10	in	in	ADP
dpc-2041	30	11	approximately	approximately	ADV
dpc-2041	30	12	10	10	NUM
dpc-2041	30	13	%	%	NOUN
dpc-2041	30	14	of	of	ADP
dpc-2041	30	15	the	the	DET
dpc-2041	30	16	patients	patient	NOUN
dpc-2041	30	17	.	.	PUNCT
dpc-2041	31	1	radiotherapy	radiotherapy	NOUN
dpc-2041	31	2	is	be	AUX
dpc-2041	31	3	usually	usually	ADV
dpc-2041	31	4	the	the	DET
dpc-2041	31	5	initial	initial	ADJ
dpc-2041	31	6	choice	choice	NOUN
dpc-2041	31	7	of	of	ADP
dpc-2041	31	8	treatment	treatment	NOUN
dpc-2041	31	9	,	,	PUNCT
dpc-2041	31	10	but	but	CCONJ
dpc-2041	31	11	chemotherapy	chemotherapy	NOUN
dpc-2041	31	12	could	could	AUX
dpc-2041	31	13	also	also	ADV
dpc-2041	31	14	be	be	AUX
dpc-2041	31	15	considered	consider	VERB
dpc-2041	31	16	.	.	PUNCT
dpc-2041	32	1	more	more	ADV
dpc-2041	32	2	recently	recently	ADV
dpc-2041	32	3	,	,	PUNCT
dpc-2041	32	4	a	a	DET
dpc-2041	32	5	study	study	NOUN
dpc-2041	32	6	by	by	ADP
dpc-2041	32	7	langley	langley	PROPN
dpc-2041	32	8	et	et	PROPN
dpc-2041	32	9	al	al	PROPN
dpc-2041	32	10	stated	state	VERB
dpc-2041	32	11	that	that	SCONJ
dpc-2041	32	12	longer	long	ADJ
dpc-2041	32	13	-	-	PUNCT
dpc-2041	32	14	term	term	NOUN
dpc-2041	32	15	(	(	PUNCT
dpc-2041	32	16	≥	≥	NOUN
dpc-2041	32	17	12	12	NUM
dpc-2041	32	18	months	month	NOUN
dpc-2041	32	19	)	)	PUNCT
dpc-2041	32	20	treatment	treatment	NOUN
dpc-2041	32	21	with	with	ADP
dpc-2041	32	22	a	a	DET
dpc-2041	32	23	tnf	tnf	PROPN
dpc-2041	32	24	alfa	alfa	NOUN
dpc-2041	32	25	inhibitor	inhibitor	NOUN
dpc-2041	32	26	,	,	PUNCT
dpc-2041	32	27	but	but	CCONJ
dpc-2041	32	28	not	not	PART
dpc-2041	32	29	shorter	short	ADJ
dpc-2041	32	30	-	-	PUNCT
dpc-2041	32	31	term	term	NOUN
dpc-2041	32	32	treatment	treatment	NOUN
dpc-2041	32	33	,	,	PUNCT
dpc-2041	32	34	was	be	AUX
dpc-2041	32	35	associated	associate	VERB
dpc-2041	32	36	with	with	ADP
dpc-2041	32	37	increased	increase	VERB
dpc-2041	32	38	risk	risk	NOUN
dpc-2041	32	39	figure	figure	NOUN
dpc-2041	32	40	2	2	NUM
dpc-2041	32	41	.	.	PUNCT
dpc-2041	32	42	(	(	PUNCT
dpc-2041	32	43	a	a	X
dpc-2041	32	44	)	)	PUNCT
dpc-2041	32	45	histopathology	histopathology	NOUN
dpc-2041	32	46	shows	show	NOUN
dpc-2041	32	47	(	(	PUNCT
dpc-2041	32	48	x10	x10	NOUN
dpc-2041	32	49	)	)	PUNCT
dpc-2041	32	50	an	an	DET
dpc-2041	32	51	acanthotic	acanthotic	ADJ
dpc-2041	32	52	epidermis	epidermis	NOUN
dpc-2041	32	53	and	and	CCONJ
dpc-2041	32	54	a	a	DET
dpc-2041	32	55	diffuse	diffuse	NOUN
dpc-2041	32	56	infiltrate	infiltrate	NOUN
dpc-2041	32	57	of	of	ADP
dpc-2041	32	58	lymphocytes	lymphocyte	NOUN
dpc-2041	32	59	and	and	CCONJ
dpc-2041	32	60	some	some	DET
dpc-2041	32	61	neutrophils	neutrophil	NOUN
dpc-2041	32	62	on	on	ADP
dpc-2041	32	63	the	the	DET
dpc-2041	32	64	dermis	dermis	NOUN
dpc-2041	32	65	.	.	PUNCT
dpc-2041	33	1	(	(	PUNCT
dpc-2041	33	2	b	b	X
dpc-2041	33	3	)	)	PUNCT
dpc-2041	33	4	histopathology	histopathology	NOUN
dpc-2041	33	5	shows	show	NOUN
dpc-2041	33	6	(	(	PUNCT
dpc-2041	33	7	x40	x40	PROPN
dpc-2041	33	8	)	)	PUNCT
dpc-2041	33	9	a	a	DET
dpc-2041	33	10	diffuse	diffuse	ADJ
dpc-2041	33	11	lymphocyte	lymphocyte	NOUN
dpc-2041	33	12	infiltrate	infiltrate	NOUN
dpc-2041	33	13	with	with	ADP
dpc-2041	33	14	irregularly	irregularly	ADV
dpc-2041	33	15	shaped	shape	VERB
dpc-2041	33	16	nuclei	nucleus	NOUN
dpc-2041	33	17	,	,	PUNCT
dpc-2041	33	18	prominent	prominent	ADJ
dpc-2041	33	19	nucleoli	nucleolus	NOUN
dpc-2041	33	20	and	and	CCONJ
dpc-2041	33	21	abundant	abundant	ADJ
dpc-2041	33	22	cytoplasm	cytoplasm	NOUN
dpc-2041	33	23	.	.	PUNCT
dpc-2041	34	1	(	(	PUNCT
dpc-2041	34	2	c	c	X
dpc-2041	34	3	)	)	PUNCT
dpc-2041	34	4	immunohistochemistry	immunohistochemistry	NOUN
dpc-2041	34	5	shows	show	NOUN
dpc-2041	34	6	cd3	cd3	VERB
dpc-2041	34	7	positive	positive	ADJ
dpc-2041	34	8	lymphocytes	lymphocyte	NOUN
dpc-2041	34	9	.	.	PUNCT
dpc-2041	35	1	(	(	PUNCT
dpc-2041	35	2	d	d	X
dpc-2041	35	3	)	)	PUNCT
dpc-2041	35	4	immunohistochemistry	immunohistochemistry	NOUN
dpc-2041	35	5	shows	show	VERB
dpc-2041	35	6	diffuse	diffuse	ADJ
dpc-2041	35	7	and	and	CCONJ
dpc-2041	35	8	strong	strong	ADJ
dpc-2041	35	9	positivity	positivity	NOUN
dpc-2041	35	10	for	for	ADP
dpc-2041	35	11	cd30	cd30	PROPN
dpc-2041	35	12	on	on	ADP
dpc-2041	35	13	neoplastic	neoplastic	ADJ
dpc-2041	35	14	cells	cell	NOUN
dpc-2041	35	15	.	.	PUNCT
dpc-2041	36	1	for	for	ADP
dpc-2041	36	2	malignancy	malignancy	NOUN
dpc-2041	36	3	[	[	X
dpc-2041	36	4	2	2	NUM
dpc-2041	36	5	]	]	PUNCT
dpc-2041	36	6	.	.	PUNCT
dpc-2041	37	1	the	the	DET
dpc-2041	37	2	patient	patient	NOUN
dpc-2041	37	3	presented	present	VERB
dpc-2041	37	4	here	here	ADV
dpc-2041	37	5	had	have	AUX
dpc-2041	37	6	been	be	AUX
dpc-2041	37	7	under	under	ADP
dpc-2041	37	8	treatment	treatment	NOUN
dpc-2041	37	9	for	for	ADP
dpc-2041	37	10	,	,	PUNCT
dpc-2041	37	11	approximately	approximately	ADV
dpc-2041	37	12	,	,	PUNCT
dpc-2041	37	13	10	10	NUM
dpc-2041	37	14	years	year	NOUN
dpc-2041	37	15	.	.	PUNCT
dpc-2041	38	1	in	in	ADP
dpc-2041	38	2	conclusion	conclusion	NOUN
dpc-2041	38	3	,	,	PUNCT
dpc-2041	38	4	studies	study	NOUN
dpc-2041	38	5	are	be	AUX
dpc-2041	38	6	controversial	controversial	ADJ
dpc-2041	38	7	regarding	regard	VERB
dpc-2041	38	8	if	if	SCONJ
dpc-2041	38	9	there	there	PRON
dpc-2041	38	10	is	be	VERB
dpc-2041	38	11	an	an	DET
dpc-2041	38	12	increased	increase	VERB
dpc-2041	38	13	risk	risk	NOUN
dpc-2041	38	14	of	of	ADP
dpc-2041	38	15	malignancy	malignancy	NOUN
dpc-2041	38	16	due	due	ADP
dpc-2041	38	17	to	to	ADP
dpc-2041	38	18	anti	anti	ADJ
dpc-2041	38	19	-	-	ADJ
dpc-2041	38	20	tnf	tnf	ADJ
dpc-2041	38	21	alfa	alfa	NOUN
dpc-2041	38	22	therapy	therapy	NOUN
dpc-2041	38	23	,	,	PUNCT
dpc-2041	38	24	with	with	ADP
dpc-2041	38	25	a	a	DET
dpc-2041	38	26	tendency	tendency	NOUN
dpc-2041	38	27	of	of	ADP
dpc-2041	38	28	relating	relate	VERB
dpc-2041	38	29	it	it	PRON
dpc-2041	38	30	to	to	ADP
dpc-2041	38	31	the	the	DET
dpc-2041	38	32	duration	duration	NOUN
dpc-2041	38	33	of	of	ADP
dpc-2041	38	34	the	the	DET
dpc-2041	38	35	treatment	treatment	NOUN
dpc-2041	38	36	.	.	PUNCT
dpc-2041	39	1	we	we	PRON
dpc-2041	39	2	presented	present	VERB
dpc-2041	39	3	a	a	DET
dpc-2041	39	4	case	case	NOUN
dpc-2041	39	5	of	of	ADP
dpc-2041	39	6	a	a	DET
dpc-2041	39	7	patient	patient	NOUN
dpc-2041	39	8	with	with	ADP
dpc-2041	39	9	a	a	DET
dpc-2041	39	10	longterm	longterm	ADJ
dpc-2041	39	11	treatment	treatment	NOUN
dpc-2041	39	12	with	with	ADP
dpc-2041	39	13	adalimumab	adalimumab	NOUN
dpc-2041	39	14	for	for	ADP
dpc-2041	39	15	psoriasis	psoriasis	NOUN
dpc-2041	39	16	and	and	CCONJ
dpc-2041	39	17	psoriatic	psoriatic	ADJ
dpc-2041	39	18	arthritis	arthritis	NOUN
dpc-2041	39	19	who	who	PRON
dpc-2041	39	20	developed	develop	VERB
dpc-2041	39	21	a	a	DET
dpc-2041	39	22	cutaneous	cutaneous	ADJ
dpc-2041	39	23	lymphoma	lymphoma	NOUN
dpc-2041	39	24	.	.	PUNCT
dpc-2041	40	1	further	further	ADJ
dpc-2041	40	2	studies	study	NOUN
dpc-2041	40	3	are	be	AUX
dpc-2041	40	4	needed	need	VERB
dpc-2041	40	5	to	to	PART
dpc-2041	40	6	determine	determine	VERB
dpc-2041	40	7	the	the	DET
dpc-2041	40	8	risk	risk	NOUN
dpc-2041	40	9	of	of	ADP
dpc-2041	40	10	lymphomas	lymphoma	NOUN
dpc-2041	40	11	in	in	ADP
dpc-2041	40	12	patients	patient	NOUN
dpc-2041	40	13	with	with	ADP
dpc-2041	40	14	long	long	ADJ
dpc-2041	40	15	term	term	NOUN
dpc-2041	40	16	anti	anti	ADJ
dpc-2041	40	17	-	-	ADJ
dpc-2041	40	18	tnf	tnf	ADJ
dpc-2041	40	19	therapy	therapy	NOUN
dpc-2041	40	20	,	,	PUNCT
dpc-2041	40	21	but	but	CCONJ
dpc-2041	40	22	physicians	physician	NOUN
dpc-2041	40	23	should	should	AUX
dpc-2041	40	24	remain	remain	VERB
dpc-2041	40	25	aware	aware	ADJ
dpc-2041	40	26	of	of	ADP
dpc-2041	40	27	this	this	DET
dpc-2041	40	28	possibility	possibility	NOUN
dpc-2041	40	29	when	when	SCONJ
dpc-2041	40	30	following	follow	VERB
dpc-2041	40	31	patients	patient	NOUN
dpc-2041	40	32	under	under	ADP
dpc-2041	40	33	this	this	DET
dpc-2041	40	34	treatment	treatment	NOUN
dpc-2041	40	35	.	.	PUNCT
dpc-2041	41	1	references	reference	NOUN
dpc-2041	41	2	1	1	NUM
dpc-2041	41	3	.	.	PUNCT
dpc-2041	41	4	wong	wong	PROPN
dpc-2041	41	5	ak	ak	PROPN
dpc-2041	41	6	,	,	PUNCT
dpc-2041	41	7	kerkoutian	kerkoutian	PROPN
dpc-2041	41	8	s	s	PROPN
dpc-2041	41	9	,	,	PUNCT
dpc-2041	41	10	said	say	VERB
dpc-2041	41	11	j	j	PROPN
dpc-2041	41	12	,	,	PUNCT
dpc-2041	41	13	rashidi	rashidi	PROPN
dpc-2041	41	14	h	h	PROPN
dpc-2041	41	15	,	,	PUNCT
dpc-2041	41	16	pullarkat	pullarkat	PROPN
dpc-2041	41	17	st	st	PROPN
dpc-2041	41	18	.	.	PROPN
dpc-2041	41	19	risk	risk	NOUN
dpc-2041	41	20	of	of	ADP
dpc-2041	41	21	lymphoma	lymphoma	NOUN
dpc-2041	41	22	in	in	ADP
dpc-2041	41	23	patients	patient	NOUN
dpc-2041	41	24	receiving	receive	VERB
dpc-2041	41	25	antitumor	antitumor	PROPN
dpc-2041	41	26	necrosis	necrosis	NOUN
dpc-2041	41	27	factor	factor	NOUN
dpc-2041	41	28	therapy	therapy	NOUN
dpc-2041	41	29	:	:	PUNCT
dpc-2041	41	30	a	a	DET
dpc-2041	41	31	meta	meta	ADJ
dpc-2041	41	32	-	-	PUNCT
dpc-2041	41	33	analysis	analysis	NOUN
dpc-2041	41	34	of	of	ADP
dpc-2041	41	35	published	publish	VERB
dpc-2041	41	36	randomized	randomize	VERB
dpc-2041	41	37	controlled	control	VERB
dpc-2041	41	38	studies	study	NOUN
dpc-2041	41	39	.	.	PUNCT
dpc-2041	42	1	clin	clin	PROPN
dpc-2041	42	2	rheumatol	rheumatol	NOUN
dpc-2041	42	3	.	.	PUNCT
dpc-2041	43	1	2012;31(4):631	2012;31(4):631	NUM
dpc-2041	43	2	-	-	PUNCT
dpc-2041	43	3	636	636	NUM
dpc-2041	43	4	.	.	PUNCT
dpc-2041	44	1	doi	doi	NOUN
dpc-2041	44	2	:	:	PUNCT
dpc-2041	44	3	10.1007/	10.1007/	NUM
dpc-2041	44	4	s10067	s10067	NOUN
dpc-2041	44	5	-	-	PUNCT
dpc-2041	44	6	011	011	NUM
dpc-2041	44	7	-	-	PUNCT
dpc-2041	44	8	1895	1895	NUM
dpc-2041	44	9	-	-	PUNCT
dpc-2041	44	10	y.	y.	NOUN
dpc-2041	44	11	pmid	pmid	PROPN
dpc-2041	44	12	:	:	PUNCT
dpc-2041	44	13	22147207.2	22147207.2	NUM
dpc-2041	44	14	.	.	PUNCT
dpc-2041	45	1	fiorentino	fiorentino	PROPN
dpc-2041	45	2	d	d	PROPN
dpc-2041	45	3	,	,	PUNCT
dpc-2041	45	4	ho	ho	PROPN
dpc-2041	45	5	v	v	NOUN
dpc-2041	45	6	,	,	PUNCT
dpc-2041	45	7	lebwohl	lebwohl	VERB
dpc-2041	45	8	mg	mg	PROPN
dpc-2041	45	9	,	,	PUNCT
dpc-2041	45	10	et	et	VERB
dpc-2041	45	11	at	at	ADP
dpc-2041	45	12	.	.	PUNCT
dpc-2041	46	1	risk	risk	NOUN
dpc-2041	46	2	of	of	ADP
dpc-2041	46	3	malignancy	malignancy	NOUN
dpc-2041	46	4	with	with	ADP
dpc-2041	46	5	systemic	systemic	ADJ
dpc-2041	46	6	psoriasis	psoriasis	NOUN
dpc-2041	46	7	treatment	treatment	NOUN
dpc-2041	46	8	in	in	ADP
dpc-2041	46	9	the	the	DET
dpc-2041	46	10	psoriasis	psoriasis	NOUN
dpc-2041	46	11	longitudinal	longitudinal	ADJ
dpc-2041	46	12	assessment	assessment	NOUN
dpc-2041	46	13	registry	registry	NOUN
dpc-2041	46	14	.	.	PUNCT
dpc-2041	47	1	j	j	PROPN
dpc-2041	47	2	am	be	AUX
dpc-2041	47	3	acad	acad	ADJ
dpc-2041	47	4	dermatol	dermatol	NOUN
dpc-2041	47	5	.	.	PUNCT
dpc-2041	48	1	2017;77(5):845	2017;77(5):845	PROPN
dpc-2041	48	2	-	-	PUNCT
dpc-2041	48	3	854	854	PROPN
dpc-2041	48	4	.	.	PUNCT
dpc-2041	48	5	doi	doi	NOUN
dpc-2041	48	6	:	:	PUNCT
dpc-2041	48	7	10.1016	10.1016	NUM
dpc-2041	48	8	/	/	SYM
dpc-2041	48	9	j.	j.	PROPN
dpc-2041	48	10	jaad.2017.07.013	jaad.2017.07.013	PROPN
dpc-2041	48	11	.	.	PUNCT
dpc-2041	49	1	pmid	pmid	NOUN
dpc-2041	49	2	:	:	PUNCT
dpc-2041	49	3	28893407	28893407	NUM
dpc-2041	49	4	.	.	PUNCT